Wilex finds US commercialisation partner for Rencarex
Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.